MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases

摘要: Cell therapy is fast emerging as a potential therapeutic option in cardiovascular therapeutics. Because of their inherent myogenic differentiation potential, skeletal myoblasts (SkMs) have been extensively assessed preclinical and clinical studies for feasibility, safety effectiveness myocardial repair. Bioheart Inc developing MyoCell, autologous SkMs delivered by MyoCath MyoStar catheter delivery systems, the treatment diseases such infarction congestive heart failure. MyoCell undergoing phase II/III development has so far demonstrated efficacy, including improvements cardiac function I/II trials.